Gross Stefanie, Geldmacher Astrid, Sharav Tumenjargal, Losch Florian, Walden Peter
Department of Dermatology, Charité - Universitätsmedizin Berlin, Humboldt University, Germany.
Vaccine. 2009 May 26;27(25-26):3398-400. doi: 10.1016/j.vaccine.2009.01.070. Epub 2009 Feb 5.
Recent investigations revealed strong immunosuppressive mechanisms in tumors that may block anti-tumor T cells and be responsible for failures of immunotherapies. Current attempts to overcome this immunosuppression include blockade of co-inhibitory factors on T cells. Reports from the respective trials indicate that the strategy can improve efficacy of therapeutic vaccination, but at the cost of severe inflammatory and autoimmune reactions. We tried to circumvent tumor-associated immunosuppression by mimotope vaccination to broaden reactive anti-tumor T cell repertoires to include T cells that have not been rendered anergic by the tumor. Initial clinical observations suggest that this strategy bears considerable promise.
最近的研究揭示了肿瘤中强大的免疫抑制机制，这些机制可能会阻断抗肿瘤T细胞，并导致免疫治疗失败。目前克服这种免疫抑制的尝试包括阻断T细胞上的共抑制因子。各试验的报告表明，该策略可以提高治疗性疫苗接种的疗效，但代价是会引发严重的炎症和自身免疫反应。我们试图通过模拟表位疫苗接种来规避肿瘤相关的免疫抑制，以扩大反应性抗肿瘤T细胞库，使其包括未被肿瘤诱导失能的T细胞。初步的临床观察表明，这一策略颇具前景。
